Abstract:Background: Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, often associated with poor prognosis and resistance to treatment. The Epidermal Growth Factor Receptor (EGFR) remains a crucial target in therapy. Methods: An advanced computational workflow was used to identify and optimize EGFR inhibitors, integrating active site prediction (CB-Dock2), ligand generation (Lead3), virtual screening (AutoDock Vina), ADMET analysis (ADMETlab 2.0), and QSAR modeling. The QSAR model was validated to ensure predictive reliability. Results: Compound g18_mol18 demonstrated a binding affinity of -9.9 kcal/mol, significantly stronger than the standard compound (-7.381 kcal/mol) (p = 0.039). Interaction analysis showed that g18_mol18 formed multiple hydrogen bonds and hydrophobic contacts with key residues. Despite its strong binding affinity, ADMET analysis highlighted challenges such as poor intestinal absorption (HIA: 0.005) and potential hepatotoxicity. However, its low hERG inhibition (0.302 vs. 0.923) indicates a lower risk of cardiotoxicity, suggesting a favorable cardiac safety profile. Conclusion: The study identifies g18_mol18 as a potent EGFR inhibitor with significantly higher binding affinity and more extensive interactions than current treatments. Although it presents pharmacokinetic challenges, these findings underline its potential as a more effective and safer alternative for NSCLC treatment, warranting further experimental validation and optimization for clinical applications. Such developments could lead to durable therapeutic responses, addressing key resistance issues seen with current EGFR inhibitors.

What problem does this paper attempt to address?

This paper attempts to solve the main problems encountered in the treatment of non - small - cell lung cancer (NSCLC), especially the resistance mechanism against EGFR inhibitors. Specifically, the research aims to design and optimize new EGFR inhibitors through computational methods to overcome the resistance problems in existing treatments and improve the effectiveness and safety of drugs. ### Main problems: 1. **High incidence and poor prognosis of NSCLC**: - NSCLC accounts for approximately 85% of all lung cancer cases and is one of the leading causes of cancer - related deaths worldwide. - Despite the progress in targeted therapies and immunotherapies, treatment resistance remains a significant obstacle, limiting long - term efficacy. 2. **Resistance to EGFR inhibitors**: - EGFR tyrosine kinase inhibitors (TKIs) perform well in initial treatment, but resistance inevitably occurs during use. - The resistance mechanisms are complex and diverse, including co - existing EGFR mutations, activation of bypass signaling pathways, and phenotypic changes (such as epithelial - mesenchymal transition). 3. **New resistance patterns of third - generation EGFR inhibitors**: - Although third - generation inhibitors (such as Osimertinib) are effective, new resistance mechanisms have also emerged, such as EGFR C797S mutation, MET amplification, and activation of the RAS - MAPK pathway. ### Research objectives: - **Anticipate resistance mechanisms in advance**: Different from traditional methods, this research takes known resistance mutations and pathway changes into account at the design stage. - **Comprehensive resistance assessment**: Use advanced computational techniques to predict and evaluate the possibility of resistance development in candidate compounds. - **Multi - target inhibition strategy**: Design inhibitors that can act on multiple resistance pathways simultaneously to overcome the limitations of single - target strategies. - **Integrate the latest clinical data**: Incorporate the latest clinical observations into the drug development process to ensure that drugs can cope with evolving resistance patterns. ### Method overview: - **Protein selection and active site prediction**: Select EGFR as the target and use CB - Dock2 to predict potential binding pockets. - **De novo ligand generation**: Use Lead3 to generate new compounds that may have high binding affinities. - **Virtual screening**: Conduct virtual screening on the generated ligand library through AutoDock Vina to select the best candidates. - **ADMET analysis**: Evaluate the absorption, distribution, metabolism, excretion, and toxicity characteristics of candidates. - **QSAR modeling**: Establish a quantitative structure - activity relationship model and verify its predictive ability. ### Result highlights: - **Strongest binding affinity**: The compound g18_mol18 shows significantly stronger binding affinity (- 9.9 kcal/mol), which is better than that of the standard compound (- 7.381 kcal/mol). - **Extensive interactions**: g18_mol18 forms multiple hydrogen bonds and hydrophobic contacts with key residues, enhancing its binding stability. - **Cardiac safety**: Despite pharmacokinetic challenges, g18_mol18 shows a lower risk of cardiotoxicity (hERG inhibition value of 0.302 vs 0.923). ### Conclusion: This research identifies g18_mol18 as a potent EGFR inhibitor with significantly higher binding affinity and more extensive interactions. Despite pharmacokinetic challenges, these findings suggest that it has the potential to be a more effective and safer alternative treatment option and is worthy of further experimental verification and optimization for clinical application. In summary, this research aims to design new EGFR inhibitors through advanced computational methods to overcome existing resistance problems, thereby improving the treatment outcomes of NSCLC patients.

Design and Optimization of Novel EGFR Inhibitors for NSCLC: A Computational Approach to Overcome Resistance Mechanisms

In Silico Exploration of Novel EGFR Kinase Mutant-Selective Inhibitors Using a Hybrid Computational Approach

Design and Optimization of Quinazoline Derivatives as Potent EGFR Inhibitors for Lung Cancer Treatment: A Comprehensive QSAR, ADMET, and Molecular Modeling Investigation

Molecular Mechanism Study of EGFR Allosteric Inhibitors Using Molecular Dynamics Simulations and Free Energy Calculations

Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches and in-vitro studies

Design, synthesis and biological evaluation of 2-phenylaminopyrimidine derivatives as EGFR inhibitors

Repurposing Antiviral Drugs as Potential Anti-EGFR Agents in NSCLC: A Structure-Based Screening and Molecular Dynamics Analysis

Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation

Identification of New EGFR Inhibitors by Structure-Based Virtual Screening and Biological Evaluation

High throughput virtual screening and validation of Plant-Based EGFR L858R kinase inhibitors against Non-Small cell lung Cancer: An integrated approach Utilizing GC-MS, network Pharmacology, Docking, and molecular dynamics

A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.

Computational identification of natural product inhibitors against EGFR double mutant (T790M/L858R) by integrating ADMET, machine learning, molecular docking and a dynamics approach

Novel bioactive 2-phenyl-4-aminopyrimidine derivatives as EGFRDel19/T790M/C797S inhibitors for the treatment of non-small cell lung cancer

Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation

Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFRT790M/C797S/L858R and EGFRT790M/L858R

Rational design and synthesis of 2,4‐dichloro‐6‐methyl pyrimidine derivatives as potential selective EGFRT790M/L858R inhibitors for the treatment of non‐small cell lung cancer

Discovery of Novel Epidermal Growth Factor Receptor (EGFR) Inhibitors Using Computational Approaches

Design, synthesis and biological evaluation of EGFR kinase inhibitors that spans the orthosteric and allosteric sites

Identifying novel and potent inhibitors of EGFR protein for the drug development against the breast cancer

Design, synthesis and bioevaluation of dual EGFR-PI3Kα inhibitors for potential treatment of NSCLC

Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer